PO:07:095 | Clinical impact of therapeutic modification following changes in AIFA reimbursement criteria for JAK inhibitors in patients with RA in remission/low disease activity: analysis of the multicenter JAK-SWAP RER study in Emilia-Romagna
Background. Since March 2023, AIFA has introduced new reimbursement criteria for JAK-inhibitors (JAKis), restricting their use to patients with rheumatoid arthritis (RA) without specific risk factors and with previous failure of bDMARD therapy. These restrictions have influenced prescribing behavio...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
PAGEPress Publications
2025-11-01
|
| Colecção: | Reumatismo |
| Assuntos: | |
| Acesso em linha: | https://www.reumatismo.org/reuma/article/view/2135 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|